Explore Stanford technologies available for licensing:

Stanford researchers have found that a chemokine receptor antagonist can reduce immunosuppression in the tumor microenvironment and thereby delay tumor progression.

The Longaker lab at Stanford University has developed a machine learning algorithm that can analyze and detect fibrotic disease.

Stanford researchers have formulated a first in line framework called EcoTyper which systematically profiles the tumor microenvironment (TME) cell states in multiple solid tumor types, providing a platform for effective personalized cancer decisions.

The blood-brain barrier (BBB) lumen is coated by a carbohydrate-rich meshwork known as the brain endothelial glycocalyx layer. Stanford researchers have shown that the brain endothelial glycocalyx is highly dysregulated during aging and neurodegenerative disease.

Researchers in the Stanford University Power Electronics Research Lab developed an effective ring electrode that removes spurious modes in piezoelectric resonators.

Technology Reference
CZ Biohub ref. no. CZB-204S-PC
Stanford ref. no. S21-067

Researchers at Stanford have developed an innovation that will enhance the depth of the imaging capabilities for optical coherence tomography (OCT) imaging.

Stanford Reference: Dockets S10-337 and S10-337B:

Researchers at Stanford University have discovered a new type of integrin-mediated cell adhesion, called curved adhesion, that represents the dominant structure in 3D physiological environments.

Stanford scientists in Dr. Paul Wender's lab have developed a novel method to synthesize tigilanol tiglate (EBC-46) and related compounds from readily available starting materials.

Researchers at Stanford have developed light-cleavable cloaking agents to control and study RNA activity in vitro and in vivo.

Researchers at Stanford have identified a novel method of use for the drug T-5224 in the prevention of abdominal adhesion.

Researchers at Stanford have developed a method for instructing the steering system of an autonomous vehicle to perform a lateral steering action, e.g., when changing lanes or repositioning within a lane.

Researchers at Stanford have advanced the concept of an "Anticipatory Control Interface" that informs the driver of a partially automated vehicle of its lateral trajectory plan.

Stanford researchers in the Goldberg lab have discovered two novel gene therapy targets for the treatment of glaucoma and other optic neuropathies. Glaucoma is the leading cause of irreversible blindness world-wide, affecting millions of adults in the United States alone.

Stanford researchers in the Goldberg lab have developed a novel method for targeted gene therapy delivery to retinal astrocytes for the treatment of glaucoma and other optic neuropathies.